Ritlecitinib higher dose

Pipeline

Status by Indication[2][1]

Competition

Competitive Landscape

2 competitors in Severe Alopecia Areata

#DrugCompanyPhaseTrials

1

Opzelura

Pfizer

Phase 3

22

Ritlecitinib Lower Dose

Pfizer

Phase 3

23

Ritlecitinib higher dose

Pfizer

Phase 3

2

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Clinical

Trials by Indication[1]

Severe Alopecia Areata2 trials

A LONG-TERM, DOUBLE-BLIND EXTENSION STUDY TO INVESTIGATE THE SAFETY AND EFFICACY OF RITLECITINIB IN PARTICIPANTS WITH SEVERE ALOPECIA AREATA WHO PREVIOUSLY COMPLETED STUDIES B7981027 OR B7981031

Recruiting·Pfizer·Phase 3·NCT07029828·140 enrolled

A PHASE 3 RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF RITLECITINIB IN PEDIATRIC PARTICIPANTS 6 TO LESS THAN 12 YEARS OF AGE WITH SEVERE ALOPECIA AREATA

Active, not recruiting·Pfizer·Phase 3·NCT07029711·208 enrolled

Details

Drug Info

Related News